Description: Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Home Page: www.virpaxpharma.com
VRPX Technical Analysis
1055 Westlakes Drive
Berwyn,
PA
19312
United States
Phone:
610 727 4597
Officers
| Name | Title |
|---|---|
| Mr. Anthony P. Mack M.B.A. | Chairman & CEO |
| Mr. Christopher M. Chipman CPA, CPA | CFO & Corp. Sec. |
| Dr. Jeffrey A. Gudin M.D. | Exec. VP, Chief Medical Officer & Director |
| Mr. Gerald W. Bruce | Exec. VP of Commercial Operations & Director |
| Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. | Chief Scientific Officer |
| Shana Panzarella | Chief of Staff |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4523 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |